Clinical and histologic signs of regression two months after initiation of treatment with dabrafenib and trametinib in a case of stage IIIc BRAF V600E-positive scalp melanoma

被引：0
|
作者：
Wei, Erin [1 ]
Cordero, Roberto Ruiz [2 ]
Zhou, Xiaolong [1 ]
Feun, Lynn [3 ]
Thomas, Giovanna [4 ]
Cho-Vega, Jeong Hee [2 ]
机构：
[1] Univ Miami, Miller Sch Med, Dept Dermatol & Cutaneous Surg, Miami, FL 33136 USA
[2] Univ Miami, Miller Sch Med, Dept Pathol, Dermatopathol, Miami, FL 33136 USA
[3] Univ Miami, Miller Sch Med, Dept Med Hematol Oncol, Miami, FL 33136 USA
[4] Univ Miami, Miller Sch Med, Dept Otolaryngol, Miami, FL 33136 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2015年 / 72卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
269
引用
收藏
页码：AB165 / AB165
页数：1
相关论文
共 41 条
  • [21] Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion
    Kocsis, Judit
    Arokszallasi, Anita
    Andras, Csilla
    Balogh, Ingrid
    Beres, Edit
    Deri, Julia
    Petak, Istvan
    Janvary, Levente
    Horvath, Zsolt
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 8 (02) : E32 - E38
  • [22] Lung Adenocarcinoma with a Rare BRAF V600E K601_W604del Mutation Responded to Dabrafenib Plus Trametinib Treatment: A Case Report
    Shimizu, J.
    Horio, Y.
    Hida, T.
    Yatabe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1049 - S1049
  • [23] Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China
    Gao, Tianfu
    Liu, Jia
    Wu, Jing
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (12)
  • [24] Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E
    Hallmeyer, Sigrun
    Gonzalez, Rene
    Lawson, David H.
    Cranmer, Lee D.
    Linette, Gerald P.
    Puzanov, Igor
    Taback, Bret
    Cowey, C. Lance
    Ribas, Antoni
    Daniels, Gregory A.
    Moore, Timothy
    Gibney, Geoffrey T.
    Tawbi, Hussein
    Whitman, Eric
    Lee, Geraldine
    Mun, Yong
    Liu, Shiyao
    Hamid, Omid
    MELANOMA RESEARCH, 2017, 27 (06) : 585 - 590
  • [25] Fast reaction and long duration—application of dabrafenib plus trametinib in treatment of metastatic melanoma with B-Raf V600E mutation: A case report
    Yang Yang
    Nanhang Lu
    Jiaqi Liu
    Jianying Gu
    Chinese Journal of Plastic and Reconstructive Surgery, 2021, 3 (04) : 193 - 196
  • [26] A novel companion diagnostic assay for BRAF V600E/K detection in melanoma: High clinical concordance of patient outcomes for trametinib and debrafenib treatment
    O'Donnell, L.
    Sweet, W.
    Lu, X.
    Meynier, F.
    Derome, A.
    Ganee, L.
    Poyet-Gelas, F.
    Martin, A.
    Casey, M.
    Kertesz, N.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S862 - S862
  • [27] Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)
    Igor Puzanov
    Journal of Translational Medicine, 13 (Suppl 1)
  • [28] Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation positive unresectable or metastatic melanoma (MM)
    Puzanov, Igor
    Callahan, Margaret K.
    Linette, Gerald P.
    Patel, Sapna Pradyuman
    Luke, Jason J.
    Sosman, Jeffrey Alan
    Wolchok, Jedd D.
    Hamid, Omid
    Minor, David R.
    Orford, Keith W.
    Hug, Bruce A.
    Ma, Bo
    Matthys, Gemma M.
    Hoos, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Successful treatment of pediatric patients with high-grade gliomas featuring leptomeningeal metastases by targeting BRAF V600E mutations with dabrafenib plus trametinib: two illustrative cases
    Kawaguchi, Yuki
    Watanabe, Yuko
    Miyakita, Yasuji
    Ohno, Makoto
    Ogawa, Chitose
    Takahashi, Masamichi
    Yanagisawa, Shunsuke
    Mukai, Takayuki
    Igaki, Hiroshi
    Sugino, Hirokazu
    Yoshida, Akihiko
    Narita, Yoshitaka
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2024, 13 (03) : 256 - 262
  • [30] Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study
    Bai, Xue
    Shaheen, Ahmed
    Grieco, Charlotte
    d'Arienzo, Paolo D.
    Mina, Florentia
    Czapla, Juliane A.
    Lawless, Aleigha R.
    Bongiovanni, Eleonora
    Santaniello, Umberto
    Zappi, Helena
    Dulak, Dominika
    Williamson, Andrew
    Lee, Rebecca
    Gupta, Avinash
    Li, Caili
    Si, Lu
    Ubaldi, Martina
    Yamazaki, Naoya
    Ogata, Dai
    Johnson, Rebecca
    Park, Benjamin C.
    Jung, Seungyeon
    Madonna, Gabriele
    Hochherz, Juliane
    Umeda, Yoshiyasu
    Nakamura, Yasuhiro
    Gebhardt, Christoffer
    Festino, Lucia
    Capone, Mariaelena
    Ascierto, Paolo Antonio
    Johnson, Douglas B.
    Lo, Serigne N.
    Long, Georgina L.
    Menzies, Alexander M.
    Namikawa, Kenjiro
    Mandala, Mario
    Guo, Jun
    Lorigan, Paul
    Najjar, Yana G.
    Haydon, Andrew
    Quaglino, Pietro
    Boland, Genevieve M.
    Sullivan, Ryan J.
    Furness, Andrew J. S.
    Plummer, Ruth
    Flaherty, Keith T.
    ECLINICALMEDICINE, 2023, 65
12345